| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA696744 | F | Effective dose required for plaque reduction in human cytomegalovirus (HCMV) was determined | Human betaherpesvirus 5 | 4 | organism-based format | Scientific Literature | ||
| 2. | ALA699361 | F | Effective dose required to reduce virus induced cytopathogenicity by Influenza A(H1N1,Fu 88) was determined; Not tested | Influenza A virus | 1 | organism-based format | Scientific Literature | ||
| 3. | ALA696970 | F | Effective dose required to reduce virus induced cytopathogenicity by Influenza B(Fu 207) was determined | Influenza B virus | 4 | organism-based format | Scientific Literature | ||
| 4. | ALA697879 | F | Effective dose required to reduce virus induced cytopathogenicity by Influenza B(singapore) was determined; Not tested | Influenza B virus | 1 | organism-based format | Scientific Literature | ||
| 5. | ALA756338 | B | Binding activity was evaluated on P3 purinoceptor-like protein from rat brain membranes by using [3H]NECA (40 nM). | Rattus norvegicus | 15 | assay format | Scientific Literature | ||
| 6. | ALA816261 | F | Effective dose required for plaque reduction in vesicular stomatitis virus (VSV) was determined | Vesicular stomatitis virus | 5 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!